Stroke Trials

Does adjunctive remote ischaemic conditioning improve 90-day functional outcomes in adults with acute supratentorial intracerebral haemorrhage managed without surgery?

After surviving an intracerebral hemorrhage, should patients with an indication for antiplatelet therapy start or avoid it?

Among patients with prior intracerebral hemorrhage, does a single pill combining three low-dose antihypertensive agents reduce recurrent stroke compared with placebo, when added to standard care?

Does recombinant factor VIIa given within 2 hours of ICH onset improve functional outcomes compared to placebo?

A pragmatic, low-tech, nurse-navigated, phone-based mHealth bundle improved 12-month systolic BP control after stroke in Ghana (67% vs 43% achieving SBP <140 mm Hg, between-group difference 24%, p<0.0...

In patients with recent cryptogenic stroke and atrial cardiopathy, does apixaban reduce incident nonlacunar covert infarcts on MRI compared to aspirin?

Can left atrial appendage closure replace NOACs for stroke prevention in anticoagulation-eligible AF patients?

Can a simple clinical score predict which ESUS patients will develop atrial fibrillation on long-term implantable cardiac monitoring?

Can the PASCAL classification system identify which patients with PFO and cryptogenic stroke will experience net benefit versus net harm from transcatheter PFO closure?

Is TRUFILL n-butyl cyanoacrylate middle meningeal artery embolization, added to standard-of-care, safe and effective in reducing residual/re-accumulation or reoperation for chronic subdural hematoma compared with standard-of-care alone?

In the MT era, in-hospital stroke continues to present with greater neurological severity, longer recognition-to-imaging times, and substantially worse in-hospital outcomes than community-onset stroke...

Is IV tenecteplase plus endovascular thrombectomy (TNK + EVT) associated with better 3-month functional outcomes compared with EVT alone in patients with anterior circulation LVO stroke treated within 4.5 hours, and does any benefit vary with expected onset-to-thrombolysis time or admission center type?

In patients with recent noncardioembolic ischemic stroke or high-risk TIA on antiplatelet therapy, does asundexian 50 mg once daily (an activated factor XI inhibitor) reduce the risk of recurrent stroke compared with placebo?

Can intravenous alteplase given 4.5 to 24 hours after acute ischemic stroke onset improve functional outcomes in patients with salvageable brain tissue and no initial plan for thrombectomy?

Among patients with acute ischemic stroke without large or medium vessel occlusion or a cardioembolic source, does IV tirofiban after an insufficient response to IV tenecteplase improve functional outcomes?

In patients with moderate acute ischaemic stroke receiving IV thrombolysis, does early oral ticagrelor plus aspirin within 6 h of onset improve functional outcomes without increasing symptomatic intracranial haemorrhage?

Does glenzocimab, a platelet GPVI antagonist, improve functional outcomes when added to IV thrombolysis (± thrombectomy) in acute ischemic stroke?

Does intravenous thrombolysis with alteplase, administered 4.5 to 24 hours after onset, improve functional outcomes in patients with posterior circulation ischemic stroke who do not have extensive early hypodensity on CT and do not undergo planned thrombectomy?

Are direct oral anticoagulants (DOACs) as safe and effective as vitamin K antagonists (VKAs) for the treatment of cerebral venous thrombosis?

Does peri-procedural subcutaneous semaglutide improve 90-day functional outcomes when added to endovascular thrombectomy in patients with acute LVO stroke who have not received intravenous thrombolysis?

Is dual antiplatelet therapy more effective than intravenous alteplase in preventing early neurological deterioration in minor strokes without large vessel occlusion compared to those with large vessel occlusion?

Can rivaroxaban prevent cognitive decline in AF patients too low-risk for standard anticoagulation?

Does starting amantadine early — before dyskinesia develops — cut the risk of levodopa-induced dyskinesia in Parkinson's disease?

Does staged bilateral MRgFUS thalamotomy provide meaningful and sustained tremor reduction — including midline tremor — with an acceptable safety profile in essential tremor patients who previously underwent unilateral treatment?

Among patients with asymptomatic high-grade carotid stenosis, does adding carotid revascularization (stenting or endarterectomy) to intensive medical management provide greater benefit than intensive medical management alone in preventing stroke?

Does revascularization reduce stroke risk when added to optimized medical therapy in patients with asymptomatic or low-to-intermediate risk symptomatic carotid stenosis?

Does remote ischemic conditioning added to IV thrombolysis increase the rate of excellent functional outcome (mRS 0-1) at 90 days in acute ischemic stroke?

Does targeted training of the ipsilesional (less impaired) arm improve motor performance in chronic stroke patients with severe contralesional arm paresis?

Does a BCI intervention using the ReHand-BCI system with robotic hand orthosis feedback produce greater upper extremity motor recovery and neuroplastic changes compared to a sham-BCI intervention in stroke patients with hand paresis?

Can cervical epidural spinal cord stimulation safely and effectively improve motor function and reduce spasticity in individuals with chronic post-stroke upper-limb hemiparesis?

What are the long-term effects (through 12 months) of vagus nerve stimulation (VNS) paired with rehabilitation on impairment, activity, and participation in people with upper extremity (UE) impairment after chronic ischemic stroke?

In patients with acute ischemic stroke undergoing endovascular thrombectomy under general anesthesia, does early extubation (<6 hours) improve 90-day functional outcomes compared with delayed extubation (6-12 hours)?

Among patients with atherosclerotic cardiovascular disease, is targeting an LDL cholesterol level of less than 55 mg per deciliter superior to targeting a level of less than 70 mg per deciliter for preventing recurrent major cardiovascular events?

What are the new clinical (ischemic stroke, intracranial/major extracranial bleeding, or death) and new MR-Imaging outcomes (ischemic or hemorrhagic brain lesions) between 3 and 6 months in patients with symptomatic, MR-imaging-verified cervical artery dissection treated with aspirin versus anticoagulation?

To compare outcomes in patients with cervical artery dissection treated with antiplatelets versus anticoagulation regarding stroke prevention and major hemorrhage.

Does minocycline, in addition to routine treatment, improve 90-day functional outcomes compared with placebo in patients with acute ischaemic stroke presenting within 72 hours of symptom onset?

Does loberamisal, a dual-acting neuroprotective agent, improve functional recovery when administered within 48 hours of moderate to severe acute ischemic stroke?

Is off-label intravenous thrombolysis safe and effective in patients with acute ischemic stroke who have recently taken direct oral anticoagulants? Does DOAC reversal with idarucizumab before IVT improve safety or efficacy outcomes?

In patients with acute LVO stroke without atrial fibrillation or intracardiac thrombus, which cardiac CT findings are independently associated with a cardioembolic stroke aetiology?

Does middle meningeal artery (MMA) embolization reduce the rate of chronic subdural hematoma (CSDH) recurrence in patients who underwent an operation and are at high risk of recurrence?

What are the complication rates of carotid artery stenting (CAS) when performed by fellowship-trained neurointerventionalists (NIRs)?

To determine whether time to treatment influences the effect of intraarterial thrombolysis (IAT), intravenous thrombolysis (IVT), and conservative standard therapy (CST) on visual outcomes in nonarteritic central retinal artery occlusion (CRAO).

Does tirzepatide improve obstructive sleep apnea severity and associated complications in adults with moderate-to-severe OSA and obesity?

Does clazosentan (15 mg/hour IV), an endothelin receptor antagonist, reduce clinical deterioration due to delayed cerebral ischemia when administered for up to 14 days alongside standard care (including nimodipine) in patients with aneurysmal subarachnoid hemorrhage and thick diffuse clot?

Does a liberal red-cell transfusion strategy, as compared with a restrictive strategy, result in a lower risk of an unfavorable neurologic outcome at 12 months in critically ill adults with acute aneurysmal subarachnoid hemorrhage and anemia?

Is galantamine safe, tolerable, and potentially efficacious in improving long-term functional and cognitive outcomes in patients with aneurysmal subarachnoid hemorrhage when administered during early and subacute stages?

Does lepodisiran, an siRNA targeting hepatic production of lipoprotein(a), safely and effectively reduce serum lipoprotein(a) concentrations over time?

Does extended head-to-heart CT angiography increase detection of cardioaortic thrombus in acute stroke or TIA without delaying treatment?